Table 2.
Ongoing trials on WJ-MSCs from clinicaltrial.gov
| Clinicaltrials.gov Identifier | Condition | First registration/phase | Treatment | Estimated enrollment | Sponsor | Final goal |
|---|---|---|---|---|---|---|
| NCT0129-1329 | Elevation myocardial infarction | February 2011/2 | Intracoronary infusion of WJ-MSCs or placebo medium into the infarct artery 4~7 days after successful reperfusion therapy | 160 | Navy General Hospital, Beijing | Investigate the efficacy of intracoronary WJ-MSCs |
| NCT0236-8587 | Ischemmic cardiomyophaty | March 2015/2 | Intracoronary infusion of WJ-MSCs or placebo in Patients with ischemic heart failure. Intravenous infusion of WJ-MSCs or placebo in Patients with ischemic heart failure |
160 | Navy General Hospital, Beijing | Investigate the therapeutic safety and efficacy of WJ-MSCs in patients with ischemic cardiomyopathy |
| NCT0116-6776 | Varices of umbilical cord | June 2010 | Isolate Wharton’s jelly matrix; test its ability to support the growth and differentiation of transplanted MSCs; perform preliminary animal test to study its ability to support bone tissue regeneration in vivo |
64 | University of Kansas Medical Center | Identifie Wharton’s jelly matrix characteristics for used in tissue engineering |
| NCT0164-9752 | Improving implantation rates | April 2015/1 | A differentiated stem cell therapy group; a undifferentiated stem cell therapy group; a control group | 60 | Kasr El Aini Hospital | Test the effect of placental derived MSC in improving implantation rates in selected patients |
| NCT0288-1476 | Amyotrophic lateral sclerosis | November 2015/1 | Group I - patients receiving intrathecally one application of WJ-MSCs Group II - patients receiving intrathecally three applications of WJ-MSCs |
30 | University of Warmia and Mazury | Investigate the tolerability of allogeneic WJ-MSCs |
| NCT0294-5449 | Erectile dysfunction | January 2017/1,2 | Dose I: Three intracavernous injections of 30×106 WJ-MSCs Dose II: Three intracavernous injections of 60×106 WJ-MSCs Dose III: Three intracavernous injections of 90×106 WJ-MSCs |
15 | Sophia Al-Adwan | Treat the erectile dysfunction in diabetic patients |
| NCT0300-3364 | Chronic traumatic spinal cord injury | December 2016/1,2 | XCEL-UMC-BETA (initial treatment)/Placebo (month 6) Placebo (initial treatment)/XCEL-UMC-BETA (month 6) |
10 | Banc de Sang i Teixits | Obtain efficacy data in intrathecal administration of expanded WJ-MSCs |
| NCT0296-3727 | Knee osteoarthrosis | January 2017/1 | Intra-articular injection of WJ-MSCs in 2 doses each of 50 million of cells | 10 | University of Jordan | Inject WJ-MSCs in patients with Knee osteoarthrosis |
| NCT0216-6294 | Diabetic foot ulcers | June 2014 | Pressure bandage; Standard of Care Cross over to NEOX. | 30 | Amniox Medical, Inc. | Evaluate the efficacy and safety of NEOX® CORD 1K in patients suffering from non-healing diabetic foot ulcers |